Mechanistically, C1q+ TAMs interact with cancer stem cells via C1q–C1q receptor signaling, modulate cytokine secretion (e.g., IL-6, MCP-1) to either promote tumor progression or, through the AMPK/JAK/STAT pathway, enhance anti-tumor immunity (29, 30). Here, CCL2 is linked to neoplasm.